Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma

Modern Pathology

Volumn 21, Issue 10, 2008, Pages 1200-1207

  Saad, Reda S ^a,c   Denning, Krista L ^a   Finkelstein, Sydney D ^b   Liu, Yulin ^a   Pereira, Telma C ^a   Lin, Xiaoqi ^a   Silverman, Jan F ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b RedPath Integrated Pathology   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

LOH; Molecular pathology; Synchronous bilateral breast carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; LYMPH NODE METASTASIS; MEDICAL TECHNOLOGY; MICROSATELLITE MARKER; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MASTECTOMY; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL;

EID: 52549084298     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.35     Document Type: Article

References (52)

1. Pomerantz RA, Murad T, Hines JR. Bilareal breast cancer. Am Surg 1989;55:441-444.
2. Kurtz JM, Amalric R, Brandone H, et al. Contralateral breast cancer and other second malignancies in patients treated by breast-conserving therapy with radiation. Int J Radiat Oncol Biol Phys 1988;15:277-284.
3. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985;68:99-112.
4. Donovan AJ. Bilateral breast cancer. Surg Clin North Am 1990;70:1141-1149.
5. Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 1984;71:711-714.
6. de la Rochefordiere A, Asselain B, Scholl S, et al. Simultaneous bilateral breast carcinomas: a retrospective review of 149 cases. Int J Radiat Oncol Biol Phys 1994;30:35-41.
7. Jobsen JJ, van der Palen J, Ong F, et al. Synchronous, bilateral breast cancer: prognostic value and incidence. Breast 2003;12:83-88.
8. Kollias J, Ellis IO, Elston CW, et al. Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg 2001;25:1117-1124.
9. Fisher ER, Fisher B, Sass R, et al., collaborating NSABP investigators. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol No. 4). Cancer 1984;54:3002-3011.
10. Kelmendi de Ustaran J, Meiss RP. Primary synchronous bilateral breast cancer: epidemiological approach. Breast Cancer Res Treat 1988;12:311-314.
11. Chunder N, Roy A, Roychoudhury S, et al. Molecular study of clonality in multifocal and bilateral tumors. Pathol Res Pract 2004;200:735-741.
12. Burns PE, Dabbs K, May C, et al. Bilateral breast cancer in northern Alberta: risk factors and survival patterns. Can Med Assoc J 1984;130:881-886.
13. Rosselli Del Turco M, Ciatto S, Perigli G, et al. Bilateral cancer of the breast. Tumori 1982;68:155-160.
14. Mueller CB, Ames F. Bilateral carcinoma of the breast: frequency and mortrality. Can J Surg 1978;21:459-465.
15. Imyanitov EN, Hanson KP. Molecular pathogenesis of bilateral breast cancer. Cancer Lett 2003;191:1-7.
16. Dawson PJ, Maloney T, Gimotty P, et al. Bilateral breast cancer; one disease or two? Breast Cancer Res Treat 1991;19:233-244.
17. Sterns EE, FletcherWA. Bilateral cancer of the breast: a review of clinical, histologic, and immunohistologic characteristics. Surgery 1991;110:617-622.
18. Kiang DT, Kennedy BJ, Snover DC. Biological and histological characteristics of simultaneous bilateral breast cancer. Lancet 1980;2:1105-1107.
19. Pandis N, Teixeira MR, Gerdes AM, et al. Chromosome abnormalities in bilateral breast carcinomas. Cytogenetic evaluation of the clonal origin of multiple primary tumors. Cancer 1995;76:250-258.
20. Imyanitov EN, Suspitsin EN, Grigoriev MY, et al. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. Int J Cancer 2002;100:557-564.
21. Shibata A, Tsai YC, Press MF, et al. Clonal analysis of bilateral breast cancer. Clin Cancer Res 1996;2:743-748.
22. Teixeira MR, Ribeiro FR, Torres L, et al. Assessment of clonal relationships in ipsilateral and bilateral multiple breast carcinomas by comparative genomic hybridization and hierarchical clustering analysis. Br J Cancer 2004;91:775-782.
23. Hungness ES, Safa M, Shaughnessy EA, et al. Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts. Surgery 2000;128:702-707.
24. Kollias J, Man S, Marafie M, et al. Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res Treat 2000;64:241-251.
25. Tse GM, Kung FY, Chan AB, et al. Clonal analysis of bilateral mammary carcinomas by clinical evaluation and partial allelotyping. Am J Clin Pathol 2003;120:168-174.
26. Hall NJ, Evans AJ, Kollias J, et al. Bilateral breast carcinomas: do they have similar mammographic features? Clin Radiol 1999;54:434-437.
27. Murphy TJ, Conant EF, Hanau CA, et al. Bilateral breast carcinoma: mammographic and histologic correlation. Radiology 1995;195:617-621.
28. Hislop TG, Elwood JM, Coldman AJ, et al. Second primary cancers of the breast: incidence and risk factors. Br J Cancer 1984;49:79-85.
29. Coradini D, Oriana S, Mariani L, et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumor? Euro J Cancer 1998;34:825-830.
30. Intra M, Rotmensz N, Viale G, et al. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer 2004;101:905-912.
31. Janschek E, Kandioler-Eckersberger D, Ludwig C, et al. Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat 2001;67:1-8.
32. Heron DE, Komarnicky LT, Hyslop T, et al. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 2000;88:2739-2750.
33. Lee MM, Chen LM, Heimann R, et al. Efficacy of breast conservation therapy in early stage bilateral breast cancer. Proc Int J Radiat Oncol Biol Phys 1996;36:281.
34. Gollamudi SV, Gelman RS, Schneider LJ, et al. Breast-conserving therapy for stage I-II synchronous bilateral breast carcinoma. Cancer 1997;79:1362-1369.
35. Mose S, Adamietz IA, Thilmann C, et al. Bilateral breast carcinoma versus unilateral disease. Review of 498 patients. Am J Clin Oncol 1997;20:541-545.
36. Tsuda H, Takarabe T, Akashi-Tanaka S, et al. Evaluation of histopathological criteria for identifying node-negative breast cancer with high risk of early recurrence in the NSAS-BC protocol study. Breast Cancer 2000;7:201-209.
37. Matsuo K, Fukutomi T, Akashi-Tanaka S, et al. Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma. Breast Cancer 2002;9:127-133.
38. Safal M, Lower EE, Hasselgren PO, et al. Bilateral synchronous breast cancer and HER-2/neu overexpression. Breast Cancer Res Treat 2002;72:195-201.
39. Tulusan AH, Ronay G, Egger H, et al. A contribution to the natural history of breast cancer. V. Bilateral primary breast cancer: incidence, risks and diagnosis of simultaneous primary cancer in the opposite breast. Arch Gynecol 1985;237:85-91.
40. Kinne DW. Special therapeutic problems: management of the contralateral breast. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds). Breast Diseases. JB Lippincott: Philadelphia, 1991, pp 827-833.
41. Green MH. Genetic of breast cancer. Mayo Clin Proc 1997;72:54-65.
42. Gollamudi SV, Gelman RS, Peiro G, et al. Breast-conserving therapy for stage I-II synchronius bilateral breast carcinoma. Cancer 1997;79:1362-1369.
43. Newman LA, Sahin AA, Cunningham JE, et al. A case-control study of unilateral and bilateral breast carcinoma patients. Cancer 2001;91:1845-1853.
44. Steinmann D, Bremer M, Rades D, et al. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer 2001;85:850-858.
45. Bremer M, Steinmann D, Dork T, et al. Bilateral breast carcinoma and local recurrence: prevalence of BRCA-1 and BRCA-2 gene mutations in an unselected patient sample. Strehlenther Onkol 2001;177:325-329.
46. Gershoni-Baruch R, Dagan E, Fried G, et al. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. Eur J Hum Genet 1999;7:833-836.
47. Fujii H, Marsh C, Cairns P, et al. Genetic divergence in the clonal evolution of breast cancer. Cancer Res 1996;56:1493-1497.
48. Agelopoulos K, Tidow N, Korsching E, et al. Molecular cytogenetic investigations of synchronous bilateral breast cancer. J Clin Pathol 2003;56:660-665.
49. Scholes AG,Woolgar JA, Boyle MA, et al. Synchronous oral carcinomas: independent or common clonal origin? Cancer Res 1998;58:2003-2006.
50. Takahashi T, Habuchi T, Kakehi Y, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998;58:5835-5841.
51. Bonsing BA, Devilee P, Cleton-Jansen AM, et al. Evidence of limited molecular genetic heterogeneity as defined by allelotyping and clonal analysis in nine metastatic breast carcinomas. Cancer Res 1993;53:3804-3811.
52. Lichy JH, Dalbegue F, Zavar M, et al. Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest 2000;80:291-301.